Product Description
The research-grade biosimilar is a humanized afucosylated monoclonal antibody that is directed against CD19. CD19 is a cell surface antigen that is expressed on pre- as well as mature B lymphocytes and is required for proliferation, differentiation, activation of B cells, and antibody production. Although the precise mechanism is not known, it is presumed that the antibody binds to CD19 located on the malignant B cell surface and results in antibody-mediated cellular cytotoxicity. The original drug received approval from the FDA in 2020 to treat neuromyelitis optica spectrum disorder (NMOSD) in patients who were anti-aquaporin 4 (AQP4) positive
Biovision | A2173 | Anti-CD19 (Inebilizumab), Humanized Antibody DataSheet
Antibody Target: CD19
Target Alternative Name: MEDI-551, MEDI 551, MEDI551, B4, CVID3,CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen
Tag Line: The biosimilar is a humanized afucosylated monoclonal antibody that specifically targets CD19 and causes antibody-dependent cellular cytolysis
Category: Biosimilars
Host: Recombinant
Isotype: IgG1, kappa
Species Reactivities: Human
Immunogen Sequence: Human CD19
Accession #: DB12530
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: Lot specific
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE